Kruppel-like-factors 4, 9 and 13 - modeling and modulating at the master regulatory borders of cell fate and cell death decisions in adrenocortical carcinoma

The human adrenal gland is a small but vital organ perched atop each kidney, acting as a chemical factory that keeps the body in balance. It produces hormones that manage everything from blood pressure and salt levels to the body's response to stress. To do this, the gland is divided into distinct layers, each with a specific job, all coordinated by a master regulator protein known as SF-1. This protein acts like a conductor, telling cells when to grow, when to specialize, and when to produce specific hormones. However, when this delicate system goes wrong, it can lead to adrenocortical carcinoma, a rare and aggressive form of cancer that arises in the outer layer of the adrenal gland. Understanding exactly how these cells decide to grow or die, and how they choose to produce hormones or stop, is crucial for finding better ways to treat the disease.

Researchers have long known that a family of proteins called Krüppel-like factors helps control cell identity, deciding whether a cell remains a stem cell or becomes a specialized one. In this study, scientists at the University Hospital Zurich and collaborating institutions set out to map how these Krüppel-like factors interact with the adrenal gland's master regulator, SF-1, in three different models of adrenal cancer. They wanted to see if these proteins work together to control the cell's fate, specifically looking at how they influence hormone production and the cell's decision to live or die. By studying three distinct cell lines derived from patients, the team discovered a complex tug-of-war between these proteins that determines whether the cancer cells continue to churn out hormones or shift toward a more aggressive, undifferentiated state.

The investigation began by examining the baseline behavior of the three cell lines: TVBF-7, NCI-H295R, and MUC-1. The researchers found that these cells were not identical; they possessed different internal landscapes. In the TVBF-7 cells, the master regulator SF-1 was highly active, while a specific Krüppel-like factor called KLF9 was present in low amounts. Conversely, in the MUC-1 cells, SF-1 was less active, and KLF9 was abundant. This suggested an inverse relationship, where high levels of the master regulator kept the Krüppel-like factor in check. To test this, the team used a technique to silence, or turn off, specific genes. When they reduced the levels of SF-1 in the TVBF-7 cells, the levels of KLF9 and another related factor, KLF13, surged. This confirmed that SF-1 normally acts as a brake on these factors. However, when they silenced KLF9 and KLF13, the levels of SF-1 did not change, indicating that the control flows primarily in one direction: the master regulator suppresses the Krüppel-like factors.

The study then explored how these proteins affect the cell's ability to produce hormones and respond to external signals. The researchers treated the cells with dexamethasone, a synthetic hormone, and angiotensin II, a substance that regulates blood pressure. They observed that dexamethasone increased the production of KLF9 in MUC-1 cells but had no effect on the other lines. Angiotensin II, meanwhile, reduced the levels of KLF13 specifically in the NCI-H295R cells. These results showed that the cells react differently to the same chemical signals depending on their internal makeup. More importantly, when the team silenced KLF9 and KLF13, they found that these factors normally help maintain the expression of receptors for glucocorticoids and androgens. Without them, the cells lost some of their ability to respond to these hormones. This suggests that KLF9 and KLF13 are not just passive bystanders but active participants in keeping the hormonal communication lines open.

Beyond hormone production, the researchers investigated how these proteins influence the cell's metabolism, specifically the handling of fats and cholesterol, which are the building blocks for steroid hormones. They looked at genes involved in lipid storage and found that when SF-1 was silenced, the expression of several metabolic genes increased significantly. This indicated that SF-1 normally suppresses these metabolic pathways to prioritize hormone production. However, KLF9 and KLF13 appeared to counteract this suppression. In the MUC-1 cells, which have a unique ability to store large amounts of fat, the researchers identified a specific protein called G0S2 that inhibits hormone production and encourages fat storage. They found that KLF9 normally suppresses G0S2; when KLF9 was silenced, G0S2 levels rose. Since G0S2 represses the enzymes needed to make steroid hormones, the suppression of G0S2 by KLF9 effectively allows hormone production to continue. When the researchers silenced G0S2 directly, the cells ramped up the production of key enzymes needed to make hormones. This revealed a specific pathway where KLF9 helps the cell choose between storing fat and making hormones.

The final piece of the puzzle involved cell death and the cell cycle, particularly in response to mitotane, the standard drug used to treat this cancer. The researchers grew the cells into three-dimensional spheres to mimic the structure of a real tumor more closely than flat cell cultures. They found that the drug mitotane triggered different responses in the different cell lines. In the NCI-H295R cells, the drug caused the cells to die through apoptosis, a programmed cell death process. In contrast, the TVBF-7 and MUC-1 cells, which are derived from metastatic tumors, were more resistant. In these resistant cells, a protein called KLF4 was highly active. KLF4 is known to pause the cell cycle to allow for DNA repair. The researchers observed that in the resistant cells, proteins involved in cell cycle arrest were stable, while in the sensitive cells, the machinery for cell death was activated. This suggests that KLF4 helps the aggressive cancer cells survive the stress of the drug by pausing their growth and repairing damage, rather than dying.

The study concludes by weaving these findings into a broader evolutionary context. The interactions between SF-1 and the Krüppel-like factors resemble ancient genetic circuits found in fruit flies, where similar proteins control the development of body segments. The researchers propose that in the adult adrenal gland, this same ancient framework is still at work, balancing the cell between a state of active hormone production and a more primitive, undifferentiated state. The balance between SF-1 and the Krüppel-like factors, particularly KLF9 and KLF13, appears to be a critical switch. When SF-1 dominates, the cell focuses on making hormones. When KLF9 and KLF13 take the upper hand, the cell may shift toward storing fat or resisting cell death. This discovery offers a new way to look at the disease, suggesting that therapies could potentially target this specific regulatory axis to force aggressive cancer cells back into a state where they are more vulnerable to treatment. The work does not offer a cure, but it provides a clearer map of the molecular borders that define cell fate in adrenocortical carcinoma.